Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the cardiac biomarkers market?

In the past few years, the market size of cardiac biomarkers has expanded exponentially. The industry, which was valued at $18.99 billion in 2024, is predicted to reach a valuation of $21.32 billion in 2025, growing at a compound annual growth rate (CAGR) of 12.3%. Several factors have spurred this growth during the historical period, including escalated healthcare expenditures, FDA endorsements, regulatory backing, the aging demographic, consciousness campaigns, high-sensitivity troponin exams, and the rise in cardiovascular ailments.

What will be the cardiac biomarkers market size in the future?

In the coming years, the cardiac biomarkers market is predicted to experience a surge in size. The market is projected to reach “$36.51 billion by 2029, with a compound annual growth rate (CAGR) of 14.4%. This growth in the forecasted timeframe is due to an increasing prevalence of chronic illnesses, heightened emphasis on disease detection in its early stages, a growing elderly population, the development of emerging markets, and a focus on biomarker panels. Key trends for this forecast period include healthcare models centered on the patient, the application of artificial intelligence and machine learning, the integration of digital health, novel technology in biomarker discovery, multi-marker panels, and the use of liquid biopsy in cardiovascular medicine.

Get your cardiac biomarkers market report here!

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report

What main drivers are fueling expansion in the cardiac biomarkers market?

The burgeoning incidence of cardiovascular diseases is likely to boost the expansion of the cardiac biomarker market. Cardiovascular diseases, which impact the heart and blood vessels, encapsulate conditions such as coronary artery disease, heart failure, and stroke. These conditions result in the release of cardiac biomarkers into the bloodstream, which can be detected through lab tests. The levels of these biomarkers offer critical diagnostic and predictive data. For instance, the British Heart Foundation released figures in September 2024, revealing that roughly 7.6 million people, 4 million males and 3.6 million females, live with heart and circulatory issues in the UK. These diseases account for almost 27% of all fatalities in the country, leading to over 170,000 deaths per year, or nearly 480 deaths per day; this translates to a death every three minutes. This escalating incidence of cardiovascular diseases is fueling the expansion of the cardiac biomarker market.

What key areas define the segmentation of the global cardiac biomarkers market?

The cardiac biomarkers market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarker Types

2) By Location Of Testing: Point Of Care Testing, Laboratory Testing

3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications

4) By End User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits, CK-Mb Diagnostic Panels

2) By Troponins: Troponin I Test Kits, Troponin T Test Kits, Troponin Diagnostic Panels

3) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels

4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits, NT-ProBNP Test Kits, Natriuretic Peptides Diagnostic Panels

5) By Ischemia Modified Albumin (IMA): IMA Test Kits, IMA Diagnostic Panels

6) By Other Biomarker Types: Heart Fatty Acid Binding Protein (HFABP), C-Reactive Protein (CRP), Other Emerging Biomarkers

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10234&type=smp

Who are the dominant players expanding their reach in the cardiac biomarkers market?

Major companies operating in the cardiac biomarkers market include bioMerieux Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Siemens AG, Thermo Fisher Scientific Inc., Creative Diagnostics, Randox Laboratories Ltd., Becton Dickinson and Company, Tosoh Corporation, Life Diagnostics, PerkinElmer Inc., Quidel Corporation, ACS Biomarker BV, LSI Medience Corp., BioDot, Alere Inc., Biosensors International Group, Biosynex SA, CardioGenics Holdings Inc., Danaher Corporation, Cortez Diagnostics Inc., DIALAB GmbH, Eurolyser Diagnostica GmbH, Grifols SA, Hologic Inc., InfraRedx Inc., Labcorp Corp., Lepu Medical Technology, Myriad Genetics, Nanosphere Inc., Biora Therapeutics Inc., Quest Diagnostics

How are evolving market trends shaping cardiac biomarkers Strategies?

One of the main developments in the cardiac biomarker market is the increasing prevalence of technological advancements. In order to maintain their market standing, organizations in this space are embracing innovative technologies. For instance, in October 2023, Mindray, a medical devices firm based in China, unveiled new high-sensitivity cardiac biomarkers, troponin I (hs-cTnI) and NT-proBNP to help enhance the detection and management of cardiovascular diseases (CVDs). The hs-cTnI biomarker is especially crucial in determining myocardial injury, known for its impressive diagnosis rate and low flaws, making it essential for early screening and risk evaluation in situations like Acute Coronary Syndrome (ACS). Conversely, NT-proBNP is a recognized marker for heart failure, aiding its detection and management by demonstrating high accuracy and little disturbance from commonly used cardiac drugs. These biomarkers collectively enhance medical decision-making in urgent heart care circumstances.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10234

Which regions are emerging as leaders in the cardiac biomarkers market?

North America was the largest region in the cardiac biomarkers market in 2024. The regions covered in the cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Cardiac Assist Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiac-assist-devices-and-equipment-global-market-report

Cardiovascular Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-devices-global-market-report

Cardiac Valve Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiac-valve-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: